title: Bromoderma.
abstract: A 3-year-old Japanese girl with severe epilepsy had been treated with potassium bromide since August 1999. The dose of potassium bromide was increased from 0.5 g/day to 0.8 g/day in May 2000 because of poor control of epilepsy. She also presented high fever, caused by bacterial pneumonia, in the same period. On June 11, a reddish eruption suddenly appeared on her back. Physical examination revealed grain-size, dark-red, erythematous papules and pustules on the back and face (Fig. 1). Some of the lesions on the back were ovoid to circular with small pustules and necrotic centers. Although some papules seemed to have dell in their centers, showing the appearance of herpes virus infection, Tzanck test was negative. A biopsy specimen obtained from one of the papules revealed a massive infiltration of eosinophils and neutrophils, forming an abscess in the epidermis and dermis (Fig. 2). The serum bromide level, which was 43.7 mEq/L (normal, 0-5 mEq/L) on May 25, increased to 114 mEq/L on June 14. The eruption disappeared within 10 days after the withdrawal of potassium bromide and treatment with topical sulfadiazine silver cream. The serum bromide decreased to 56.8 mEq/L on July 6.
authors.affiliation: Department of Dermatology and Pediatrics, Oita Medical University, Oita, Japan. anzai@oita-med.ac.jp
authors.forename: Saburo
authors.initials: S
authors.lastname: Anzai
authors.forename: Sakuhei
authors.initials: S
authors.lastname: Fujiwara
authors.forename: Miki
authors.initials: M
authors.lastname: Inuzuka
mesh_terms: D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects*; D001965:Bromides / Q000008:administration & dosage / Q000009:adverse effects*; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology*; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D017680:Potassium Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D012837:Silver Sulfadiazine / Q000627:therapeutic use; D012872:Skin Diseases, Vesiculobullous / Q000139:chemically induced* / Q000188:drug therapy
chemical_list: D000891:Anti-Infective Agents, Local; D000927:Anticonvulsants; D001965:Bromides; D017680:Potassium Compounds; C039004:potassium bromide; D012837:Silver Sulfadiazine